Targeted Therapy in Children: — What Parents Need to Know

Yes, targeted therapy is used for several childhood cancers where biomarker testing shows the right molecular target is present. Examples include certain leukaemias with specific chromosomal changes, some brain tumours with identifiable genetic mutations, and a group of tumours defined by gene fusions regardless of which organ they arise in. The question is always whether your child's specific tumour has the marker that predicts response — and that is decided by testing, not by the diagnosis label alone.

Doses are calculated from body surface area — a value derived from your child's height and weight together — rather than from adult weight-based tables. This means the dose is rechecked whenever your child has a significant change in size, because children grow during what can be a long treatment course. For some agents, drug level testing is also used to confirm the dose is in the right range for your child specifically, and adjustments are made accordingly.

Targeted therapy is used in certain leukaemias carrying specific chromosomal changes, in low-grade gliomas with identified genetic alterations, in tumours across different organs defined by particular gene fusions, and in a small number of other solid tumours with actionable biomarkers. The list continues to expand as molecular testing becomes more routine in paediatric oncology. Your child's oncologist can tell you whether your child's tumour has been tested and what the result showed.

Some targeted agents can affect growth hormone secretion, bone development or thyroid function, all of which influence how a child grows. This is why growth measurements and hormone checks are part of standard monitoring throughout treatment. If an effect is detected, it can often be managed — for instance, hormone support if thyroid levels fall. Growth is also monitored for years after treatment ends, because some effects appear late rather than during the treatment course itself.

Many children do continue attending school during targeted therapy, particularly because targeted agents often have a different side-effect profile from chemotherapy and are taken by mouth at home rather than needing frequent hospital visits. Whether school is practical depends on how your child feels, what their blood results are showing, and the school's ability to accommodate any needs. Your oncology team can provide a letter for the school explaining any adjustments required, such as precautions around children with active infections.

This is a practical issue your oncology team will plan for in advance. Some targeted agents are available in dispersible or liquid formulations suitable for younger children. Others can be mixed or dissolved if the manufacturer's evidence supports this — your team will not advise altering a formulation without first confirming it is safe to do so. If swallowing is a concern, raise it before treatment starts so the right formulation is confirmed from the first dose rather than becoming a problem mid-treatment.

Long-term follow-up typically continues for several years after treatment ends, and for some effects the monitoring extends into adulthood. Effects on growth, hormone function, heart health and bone development can appear well after the last dose. COG and NCCN guidance includes specific late-effects surveillance schedules that vary by agent type. Your child's oncology team will give you a written follow-up plan showing what is being checked, how often, and which results would prompt a referral.

Yes. Targeted therapy is administered as day care at CION centres, and treatment planning follows published COG and NCCN paediatric protocols for dosing and monitoring. Biomarker testing to establish eligibility is arranged through the treating oncologist. Response-assessment scans such as PET-CT are coordinated with partner imaging centres. If the treatment being considered is one CION does not provide — such as CAR-T or cell therapy — you will be referred to a centre that offers it.